New York, NY, March 21, 2025 (GLOBE NEWSWIRE) —
Key Findings:
- This study demonstrates that tailored vaccines targeting patient-specific neoantigens (proteins that can trigger an immune response against cancer) can generate a potent immune response, with early data suggesting a correlation with improved long-term survival.
- A personalized multi-peptide neoantigen cancer vaccine called PGV001, using relatively few antigens (compared to recently published trials by other researchers) was sufficient to induce a strong immune response across multiple cancer types.
- Thirteen patients treated across five tumor types (non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, and multiple myeloma) experienced positive outcomes.
- Early results show that PGV001 did not cause serious side…